Form 8-K - Current report:
SEC Accession No. 0001213900-22-038873
Filing Date
2022-07-12
Accepted
2022-07-12 16:15:22
Documents
15
Period of Report
2022-07-12
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea162746-8k_citius.htm   iXBRL 8-K 27905
2 PRESS RELEASE ea162746-8kex99i_citius.htm EX-99.1 12168
3 GRAPHIC image_001.jpg GRAPHIC 4477
  Complete submission text file 0001213900-22-038873.txt   267773

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ctxr-20220712.xsd EX-101.SCH 3681
5 XBRL DEFINITION FILE ctxr-20220712_def.xml EX-101.DEF 26572
6 XBRL LABEL FILE ctxr-20220712_lab.xml EX-101.LAB 36574
7 XBRL PRESENTATION FILE ctxr-20220712_pre.xml EX-101.PRE 25196
9 EXTRACTED XBRL INSTANCE DOCUMENT ea162746-8k_citius_htm.xml XML 5349
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38174 | Film No.: 221079314
SIC: 2834 Pharmaceutical Preparations